Analysts Set Encompass Health Co. (NYSE:EHC) Target Price at $122.71

Encompass Health Co. (NYSE:EHC - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $122.71.

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Encompass Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 24th. UBS Group increased their target price on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Barclays lifted their price target on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Truist Financial reissued a "buy" rating and issued a $135.00 price objective (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. Finally, William Blair restated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th.

Insider Activity at Encompass Health

In other news, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the sale, the chief executive officer now owns 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP John Patrick Darby sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,663 shares of company stock valued at $16,034,082. 2.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. WPG Advisers LLC acquired a new stake in shares of Encompass Health in the first quarter valued at about $27,000. Colonial Trust Co SC bought a new stake in Encompass Health during the 4th quarter valued at approximately $29,000. Transce3nd LLC acquired a new stake in Encompass Health in the 4th quarter valued at approximately $40,000. CBIZ Investment Advisory Services LLC increased its position in Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Encompass Health by 749.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company's stock worth $42,000 after buying an additional 367 shares during the last quarter. Institutional investors own 97.25% of the company's stock.

Encompass Health Price Performance

Shares of NYSE EHC traded down $0.33 during trading on Friday, hitting $120.58. The company had a trading volume of 240,786 shares, compared to its average volume of 784,724. The company has a market cap of $12.15 billion, a P/E ratio of 27.03, a PEG ratio of 2.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The business's 50-day moving average is $109.93 and its 200 day moving average is $102.01. Encompass Health has a 52 week low of $82.74 and a 52 week high of $122.08.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Encompass Health's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.12 earnings per share. Equities research analysts predict that Encompass Health will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.56%. Encompass Health's dividend payout ratio is 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.